Panacea Biotec shares surged 5.00% to hit the upper circuit limit at RS. 538.90, rising by 25.65 points from its previous close of RS. 513.25 on the BSE.

The stock opened at RS. 524.05 and recorded an intraday high of RS. 538.90 and a low of RS. 520.15. A total of 35,427 shares have changed hands so far.

Classified under BSE group 'B', the stock with a face value of RS. 1 touched a 52-week high of RS. 549.05 on April 21, 2025, and a 52-week low of RS. 112.70 on June 4, 2024. Over the last week, the scrip traded between RS. 549.05 and RS. 496.85. The company's market capitalization currently stands at RS. 3294.07 crore.

The company’s shareholding pattern includes 72.48% held by promoters, 2.65% by institutions, and 24.87% by non-institutional investors.

The rally follows Panacea Biotec’s announcement of receiving an additional order from the United Nations International Children's Emergency Fund (UNICEF) for supplying 40 million doses of its bivalent oral polio vaccine (bOPV) in Q3CY2025. The order is valued at approximately $5.20 million (around RS. 44 crore).

Panacea Biotec is a prominent research-driven biotechnology company with robust capabilities in research, manufacturing, and marketing.